Eric Jonasch, MD, University of Texas MD Anderson Cancer Center

Articles by Eric Jonasch, MD, University of Texas MD Anderson Cancer Center

Renal Cell Carcinoma: Future Evolutions in Care

ByBrian I. Rini, MD, Cleveland Clinic,Eric Jonasch, MD, University of Texas MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO

July 24th 2023

Shared insight on the evolving state of renal cell carcinoma management and hope for future growth in the treatment landscape.

Selecting Optimal Therapy for Advanced Non-Clear Cell RCC

ByDiscussant: Brian I. Rini, MD, Cleveland Clinic,Eric Jonasch, MD, University of Texas MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO

July 24th 2023

Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.

Dosing Strategies With First-Line Therapy in Advanced Clear Cell RCC

ByBrian I. Rini, MD,Eric Jonasch, MD, University of Texas MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO

July 3rd 2023

Panelists consider best practices in dosing while managing patients on first-line therapy for advanced clear cell renal cell carcinoma.

Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies

July 3rd 2023

Expert perspectives on the adverse event profiles of first-line combination therapies in the advanced clear cell renal cell carcinoma space.

Factors in Selecting First-Line Therapy for Patients With Advanced Clear Cell RCC

June 26th 2023

A brief discussion on the patient and disease characteristics that help to inform selection of best therapy for patients with advanced clear cell renal cell carcinoma.